The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
Wellcome Trust Case Control Consortium, & The Australo-Anglo-American Spondylitis Consortium (TASC) (2007) · Nature Genetics · doi:10.1038/ng.2007.17 · Cited by 1,374
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Self-citationJak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Tefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Self-citationHydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Polycythemia Vera: Stem-Cell and Probable Clonal Origin of the Disease
Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F., & Steinmann, L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197610212951702 · Cited by 640
Defective Lymphoid Development in Mice Lacking Jak3
Nosaka, T., van Deursen, J. M. A., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., Doherty, P. C., Grosveld, G. C., & Ihle, J. N. (1995) · Science · doi:10.1126/science.270.5237.800 · Cited by 637
Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T., Allebach, J., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-11-3775 · Cited by 632
Self-citationJAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 622
Identification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 562
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Peeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H., et al. (1997) · Blood · doi:10.1182/blood.v90.7.2535 · Cited by 491
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R. M., Finazzi, G., Guerini, V., Fabris, F., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064287 · Cited by 449
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., & Skoda, R. C. (2008) · Blood · doi:10.1182/blood-2007-08-107748 · Cited by 440
Lacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., & Villeval, J.-L. (2006) · Blood · doi:10.1182/blood-2006-02-002030 · Cited by 435
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131664 · Cited by 431
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Partial Impairment of Cytokine Responses in Tyk2-Deficient Mice
Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00054-6 · Cited by 420
Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S., Chopra, R., Clark, R., Levis, M. J., & Small, D. (2006) · Blood · doi:10.1182/blood-2006-04-015560 · Cited by 413
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Jones, A. V., Chase, A., Silver, R. T., Oscier, D., Zoi, K., Wang, Y. L., Cario, H., Pahl, H. L., Collins, A., Reiter, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.334 · Cited by 399
Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., et al. (2009) · Blood · doi:10.1182/blood-2009-07-234880 · Cited by 396
Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 395
Wernig, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., Gozo, M., McDowell, E. P., Levine, R. L., Doukas, J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.009 · Cited by 390
Cytokines and immunodeficiency diseases
Leonard, W. J. (2001) · Nature Reviews Immunology · doi:10.1038/35105066 · Cited by 390
Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194548 · Cited by 378
Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J. T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H. M., & Issa, J.-P. J. (2005) · Blood · doi:10.1182/blood-2005-05-1800 · Cited by 369
Self-citationRegulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Olcaydu, D., Harutyunyan, A., Jäger, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H., & Kralovics, R. (2009) · Nature Genetics · doi:10.1038/ng.341 · Cited by 362
Kilpivaara, O., Mukherjee, S., Schram, A. M., Wadleigh, M., Mullally, A., Ebert, B. L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., et al. (2009) · Nature Genetics · doi:10.1038/ng.342 · Cited by 349
Self-citationMutations of ASXL1 gene in myeloproliferative neoplasms
Carbuccia, N., Murati, A., Trouplin, V, Brecqueville, M., Adélaïde, J., Rey, J., Vainchenker, W., Bernard, O. A., Chaffanet, M., Vey, N., et al. (2009) · Leukemia · doi:10.1038/leu.2009.141 · Cited by 331
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., & Gotlib, J. (2010) · Blood · doi:10.1182/blood-2010-02-270108 · Cited by 330
Theocharides, A., Boissinot, M., Girodon, F., Garand, R., Teo, S.-S., Lippert, E., Talmant, P., Tichelli, A., Hermouet, S., & Skoda, R. C. (2007) · Blood · doi:10.1182/blood-2006-12-062125 · Cited by 326
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 326
Self-citationShimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., Yamashita, M., Numata, A., Takase, K., Kobayashi, S., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00055-8 · Cited by 319
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
The Jak-Stat pathway in normal and perturbed hematopoiesis
Ward, A. C., Touw, I., & Yoshimura, A. (2000) · Blood · doi:10.1182/blood.v95.1.19 · Cited by 313
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Kawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y. Q., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E., Ortaldo, J. R., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6374 · Cited by 302
Impaired Expression of the Thrombopoietin Receptor by Platelets from Patients with Polycythemia Vera
Moliterno, A. R., Hankins, W. D., & Spivak, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380903 · Cited by 302
Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101576 · Cited by 298
Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Jamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., Jones, C., Zehnder, J. L., Lilleberg, S. L., & Weissman, I. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601462103 · Cited by 286
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A., & Beer, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278
Pardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2413 · Cited by 266
Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.
Gilliland, D. G., Blanchard, K. L., Levy, J., Perrin, S., & Bunn, H. F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6848 · Cited by 253
Barbui, T., Barosi, G., Grossi, A., Gugliotta, L., Liberato, L. N., Marchetti, M., Mazzucconi, M. G., Rodeghiero, F., & Tura, S. (2004) · PubMed · Cited by 253
Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083402 · Cited by 252
Akada, H., Yan, D., Zou, H., Fiering, S., Hutchison, R. E., & Mohi, M. G. (2010) · Blood · doi:10.1182/blood-2009-04-215848 · Cited by 249
Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., Ross, T. S., Peeters, P., Van Rompaey, L., Van Etten, R. A., Ilaria, R., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5321 · Cited by 245
Tyner, J. W., Bumm, T. G., Deininger, J., Wood, L., Aichberger, K. J., Loriaux, M. M., Druker, B. J., Burns, C. J., Fantino, E., & Deininger, M. W. (2010) · Blood · doi:10.1182/blood-2009-05-223727 · Cited by 240
Passamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., Kiladjian, J.-J., McMullin, M. F., Ruggeri, M., Besses, C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-316810 · Cited by 236
Lippert, E., Boissinot, M., Kralovics, R., Girodon, F., Dobo, I., Praloran, V., Boiret-Dupré, N., Skoda, R. C., & Hermouet, S. (2006) · Blood · doi:10.1182/blood-2006-01-013540 · Cited by 234
Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J., & Verstovsek, S. (2010) · Blood · doi:10.1182/blood-2009-10-246363 · Cited by 233
Self-citationExpression of Bcl-x in Erythroid Precursors from Patients with Polycythemia Vera
Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I., & Fernández-Luna, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380902 · Cited by 229
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., et al. (2008) · Blood · doi:10.1182/blood-2008-01-135897 · Cited by 222
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Zaleskas, V. M., Krause, D. S., Lazarides, K., Patel, N., Hu, Y., Li, S., & Van Etten, R. A. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000018 · Cited by 220
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Xing, S., Wanting, T. H., Zhao, W., Ma, J., Wang, S., Xu, X., Li, Q., Fu, X., Xu, M., & Zhao, Z. J. (2008) · Blood · doi:10.1182/blood-2007-05-091579 · Cited by 213
Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2404948 · Cited by 212
Pardanani, A., Lasho, T., Smith, G., Burns, C. J., Fantino, E., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.50 · Cited by 207
Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease
Bumm, T. G. P., Elsea, C., Corbin, A. S., Loriaux, M., Sherbenou, D., Wood, L., Deininger, J., Silver, R. T., Druker, B. J., & Deininger, M. W. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2210 · Cited by 198
Dupont, S., Massé, A., James, C., Teyssandier, I., Lécluse, Y., Larbret, F., Ugo, V., Saulnier, P., Koscielny, S., Le Couédic, J. P., et al. (2007) · Blood · doi:10.1182/blood-2006-10-054940 · Cited by 197
Williams, R. T., Roussel, M. F., & Sherr, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602030103 · Cited by 193
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 184
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Marubayashi, S., Koppikar, P., Taldone, T., Abdel-Wahab, O., West, N., Bhagwat, N., Caldas-Lopes, E., Ross, K. N., Gönen, M., Gozman, A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42442 · Cited by 184
The haematocrit and platelet target in polycythemia vera
Di Nisio, M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06430.x · Cited by 183
Delhommeau, F., Dupont, S., Tonetti, C., Massé, A., Godin, I., Couedic, J.-P. L., Debili, N., Saulnier, P., Casadevall, N., Vainchenker, W., et al. (2007) · Blood · doi:10.1182/blood-2006-03-007146 · Cited by 178
JAK signaling globally counteracts heterochromatic gene silencing
Shi, S., Calhoun, H. C., Xia, F., Li, J., Le, L., & Li, W. X. (2006) · Nature Genetics · doi:10.1038/ng1860 · Cited by 177
Wang, Y., Fiskus, W., Chong, D. G., Buckley, K. M., Natarajan, K., Rao, R., Joshi, A., Balusu, R., Koul, S., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222133 · Cited by 177
Safar, V., Gastinne, T., Milpied, N., Maisonneuve, H., Morineau, N., Dubruille, V., Mahé, B., Moreau, P., Jardel, H., Planche, L., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2190.2190 · Cited by 168
Ugo, V., Marzac, C., Teyssandier, I., Larbret, F., Lécluse, Y., Debili, N., Vainchenker, W., & Casadevall, N. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.11.003 · Cited by 166
Busque, S., Leventhal, J. R., Brennan, D. C., Steinberg, S., Klintmalm, G. B., Shah, T., Mulgaonkar, S., Bromberg, J. S., Vincenti, F., Hariharan, S., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02720.x · Cited by 157
Quintás‐Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D. A., Cortes, J. E., Ravandi, F., Garcia‐Manero, G., Ferrajoli, A., Bueso-Ramos, C., & Verstovšek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6548 · Cited by 154
Self-citationLNKMutations inJAK2Mutation–Negative Erythrocytosis
Lasho, T. L., Pardanani, A. D., & Tefferi, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1006966 · Cited by 151
Najean, Y., & Rain, J. (1997) · Blood · doi:10.1182/blood.v89.7.2319 · Cited by 149
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
Jäger, R., Gisslinger, H., Passamonti, F., Rumi, E., Berg, T., Gisslinger, B., Pietra, D., Harutyunyan, A. S., Klampfl, T., Olcaydu, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.99 · Cited by 148
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Ishii, T., Bruno, E., Hoffman, R., & Xu, M. (2006) · Blood · doi:10.1182/blood-2006-04-017392 · Cited by 148
Coombs, J. H., Bloom, B. J., Breedveld, F. C., Fletcher, M. P., Gruben, D. C., Kremer, J. M., Burgos‐Vargas, R., Wilkinson, B. E., Zerbini, C. A. F., & Zwillich, S. H. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108159 · Cited by 145
Mesa, R. A., Yao, X., Cripe, L. D., Li, C., Litzow, M. R., Paietta, E. M., Rowe, J. M., Tefferi, A., & Tallman, M. S. (2010) · Blood · doi:10.1182/blood-2010-05-287417 · Cited by 138
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D., & O’Shea, J. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00220.x · Cited by 134
Jiang, J., Ghoreschi, K., Deflorian, F., Chen, Z. J., Perreira, M., Pesu, M., Smith, J. A., Nguyễn, Ð.-T., Liu, E. H., Leister, W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801142b · Cited by 131
Samanta, A. K., Chakraborty, S. N., Wang, Y., Kantarjian, H. M., Sun, X., Hood, J. D., Perrotti, D., & Arlinghaus, R. B. (2009) · Oncogene · doi:10.1038/onc.2009.7 · Cited by 127
Self-citationThe chronic myeloproliferative disorders: Clonality and clinical heterogeneity
Spivak, J. L. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.02.011 · Cited by 127
Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Baffert, F., Régnier, C. H., Pover, A. D., Pissot‐Soldermann, C., Tavares, G., Blasco, F., Brueggen, J., Chêne, P., Drueckes, P., Erdmann, D., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0053 · Cited by 126
Lnk constrains myeloproliferative diseases in mice
Bersenev, A., Wu, C., Balcerek, J., Jiang, J., Kundu, M., Blobel, G. A., Chikwava, K. R., & Tong, W. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42032 · Cited by 114
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Xiang, Z., Zhao, Y., Mitaksov, V., Fremont, D. H., Kasai, Y., Molitoris, A., Ries, R. E., Miner, T. L., McLellan, M. D., DiPersio, J. F., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090308 · Cited by 110
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
Chaligné, R., James, C., Tonetti, C., Besancenot, R., Couédic, J. L., Fava, F., Mazurier, F., Godin, I., Maloum, K., Larbret, F., et al. (2007) · Blood · doi:10.1182/blood-2007-05-089003 · Cited by 109
How I treat symptomatic splenomegaly in patients with myelofibrosis
Mesa, R. A. (2009) · Blood · doi:10.1182/blood-2009-02-195974 · Cited by 97
Marshall, J. L., Kindler, H. L., Deeken, J. F., Bhargava, P., Vogelzang, N. J., Rizvi, N. A., Luhtala, T., Boylan, S., Dordal, M. S., Robertson, P., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000047103.64335.b0 · Cited by 97
A Role for JAK2 Mutations in Myeloproliferative Diseases
Morgan, K. J., & Gilliland, D. G. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.154159 · Cited by 94
Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling
Ho, J. M.-Y., Beattie, B. K., Squire, J. A., Frank, D. A., & Barber, D. L. (1999) · Blood · doi:10.1182/blood.v93.12.4354 · Cited by 94
STAT3 is constitutively active in some patients with Polycythemia rubra vera
Röder, S., Steimle, C., Meinhardt, G., & Pahl, H. L. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00637-3 · Cited by 93
van Gurp, E., Weimar, W. W., Gaston, R. S., Brennan, D. C., Mendez, R., Pirsch, J. D., Swan, S. K., Pescovitz, M. D., Ni, G., Wang, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02307.x · Cited by 76
Aberrant signal transduction pathways in myeloproliferative neoplasms
Kota, J., Cáceres, N. E., & Constantinescu, S. N. (2008) · Leukemia · doi:10.1038/leu.2008.236 · Cited by 73
Shah, N. P., Olszynski, P., Sokol, L., Verstovšek, S., Hoffman, R., List, A. F., Cortes, J. E., Kantarjian, H. M., Gilliland, D. G., Clary, D. O., et al. (2008) · Blood · doi:10.1182/blood.v112.11.98.98 · Cited by 68
Self-citationDusa, A., Staerk, J., Elliott, J., Pecquet, C., Poirel, H. A., Johnston, J. A., & Constantinescu, S. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709302200 · Cited by 67
Manshouri, T., Quintás‐Cardama, A., Nussenzveig, R. H., Gaikwad, A. S., Estrov, Z. E., Prchal, J. T., Cortes, J. E., Kantarjian, H. M., & Verstovšek, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00817.x · Cited by 60
Self-citationChoosing between stem cell therapy and drugs in myelofibrosis
Kröger, N. M., & Mesa, R. A. (2008) · Leukemia · doi:10.1038/sj.leu.2405080 · Cited by 57
Komura, E., Chagraoui, H., Mas, V. M., Blanchet, B., Sepulveda, P. D., Larbret, F., Larghero, J., Tulliez, M., Debili, N., Vainchenker, W., et al. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00085-7 · Cited by 53
Verstovšek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P. J., Levy, R., Bradley, E. C., Schacter, L., Garrett, W. M., Vaddi, K., et al. (2009) · Blood · doi:10.1182/blood.v114.22.311.311 · Cited by 48
Self-citationPathogenesis and management of essential thrombocythemia
Beer, P. A., & Green, A. R. (2009) · Hematology · doi:10.1182/asheducation-2009.1.621 · Cited by 45
Verstovšek, S., Kantarjian, H. M., Pardanani, A. D., Thomas, D. A., Cortes, J. E., Mesa, R. A., Redman, J. R., Staschen, C., Fridman, J. S., Vaddi, K., et al. (2007) · Blood · doi:10.1182/blood.v110.11.558.558 · Cited by 45
Self-citationPardanani, A. D., Gotlib, J. R., Jamieson, C. H. M., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Shorr, J. S., Gilliland, D. G., & Tefferi, A. (2009) · Blood · doi:10.1182/blood.v114.22.755.755 · Cited by 40
Self-citationNovel Immunosuppression: Small Molecules and Biologics
Yabu, J. M., & Vincenti, F. G. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.03.009 · Cited by 37
A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera
PAQUETTE, R. L., Sokol, L., Shah, N. P., Silver, R. T., List, A. F., Clary, D. O., Bui, L. A., & Talpaz, M. (2008) · Blood · doi:10.1182/blood.v112.11.2810.2810 · Cited by 34
Hexner, E. O., Goldberg, J. D., Prchal, J. T., Demakos, E. P., Swierczek, S. I., Weinberg, R. S., Tripodi, J., Najfeld, V., Carroll, M. P., Marchioli, R., et al. (2009) · Blood · doi:10.1182/blood.v114.22.754.754 · Cited by 32
Miscreant myeloproliferative disorder stem cells
Jamieson, C. H. M., Barroga, C. F., & Vainchenker, W. (2008) · Leukemia · doi:10.1038/leu.2008.290 · Cited by 23
Liu, P. C. C., Caulder, E., Li, J., Waeltz, P., Margulis, A., Wynn, R., Becker-Pasha, M., Li, Y., Crowgey, E. L., Hollis, G. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1298 · Cited by 20
Cited by
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 485
Self-citationBiology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
Metadata
- Authors
- Quintás-Cardama, A., Kantarjian, H., Cortes, J., & Verstovsek, S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-02
- Volume
- 10
- Issue
- 2
- Pages
- 127-140
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2023680965
- Cited by
- 290
- References
- 143
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.